BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37902007)

  • 1. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
    Prekovic S; Chalkiadakis T; Roest M; Roden D; Lutz C; Schuurman K; Opdam M; Hoekman L; Abbott N; Tesselaar T; Wajahat M; Dwyer AR; Mayayo-Peralta I; Gomez G; Altelaar M; Beijersbergen R; Győrffy B; Young L; Linn S; Jonkers J; Tilley W; Hickey T; Vareslija D; Swarbrick A; Zwart W
    EMBO Mol Med; 2023 Dec; 15(12):e17737. PubMed ID: 37902007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
    Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
    Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.
    West DC; Pan D; Tonsing-Carter EY; Hernandez KM; Pierce CF; Styke SC; Bowie KR; Garcia TI; Kocherginsky M; Conzen SD
    Mol Cancer Res; 2016 Aug; 14(8):707-19. PubMed ID: 27141101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
    West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
    Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
    [No Abstract]   [Full Text] [Related]  

  • 5. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.
    Pan D; Kocherginsky M; Conzen SD
    Cancer Res; 2011 Oct; 71(20):6360-70. PubMed ID: 21868756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
    Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
    Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone receptors in breast cancer: more than estrogen receptors.
    Lamb CA; Vanzulli SI; Lanari C
    Medicina (B Aires); 2019; 79(Spec 6/1):540-545. PubMed ID: 31864223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT3 and GR Cooperate to Drive Gene Expression and Growth of Basal-Like Triple-Negative Breast Cancer.
    Conway ME; McDaniel JM; Graham JM; Guillen KP; Oliver PG; Parker SL; Yue P; Turkson J; Buchsbaum DJ; Welm BE; Myers RM; Varley KE
    Cancer Res; 2020 Oct; 80(20):4355-4370. PubMed ID: 32816914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression.
    Kinyamu HK; Archer TK
    Mol Cell Biol; 2003 Aug; 23(16):5867-81. PubMed ID: 12897156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer.
    Buxant F; Engohan-Aloghe C; Noël JC
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):254-7. PubMed ID: 19875955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) α and activator protein 1 (AP1) in dexamethasone-mediated interference of ERα activity.
    Karmakar S; Jin Y; Nagaich AK
    J Biol Chem; 2013 Aug; 288(33):24020-34. PubMed ID: 23814048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogramming the chromatin landscape: interplay of the estrogen and glucocorticoid receptors at the genomic level.
    Miranda TB; Voss TC; Sung MH; Baek S; John S; Hawkins M; Grøntved L; Schiltz RL; Hager GL
    Cancer Res; 2013 Aug; 73(16):5130-9. PubMed ID: 23803465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer.
    Gandhi S; Elkhanany A; Oshi M; Dai T; Opyrchal M; Mohammadpour H; Repasky EA; Takabe K
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial Ishikawa cells.
    Rocha W; Sanchez R; Deschênes J; Auger A; Hébert E; White JH; Mader S
    Mol Pharmacol; 2005 Dec; 68(6):1852-62. PubMed ID: 16186250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
    Kinyamu HK; Collins JB; Grissom SF; Hebbar PB; Archer TK
    Mol Carcinog; 2008 Nov; 47(11):845-85. PubMed ID: 18381591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
    Xu G; Chhangawala S; Cocco E; Razavi P; Cai Y; Otto JE; Ferrando L; Selenica P; Ladewig E; Chan C; Da Cruz Paula A; Witkin M; Cheng Y; Park J; Serna-Tamayo C; Zhao H; Wu F; Sallaku M; Qu X; Zhao A; Collings CK; D'Avino AR; Jhaveri K; Koche R; Levine RL; Reis-Filho JS; Kadoch C; Scaltriti M; Leslie CS; Baselga J; Toska E
    Nat Genet; 2020 Feb; 52(2):198-207. PubMed ID: 31932695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid receptor-IRS-1 axis controls EMT and the metastasis of breast cancers.
    Shi W; Wang D; Yuan X; Liu Y; Guo X; Li J; Song J
    J Mol Cell Biol; 2019 Dec; 11(12):1042-1055. PubMed ID: 30726932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glucocorticoid receptor interferes with progesterone receptor-dependent genomic regulation in breast cancer cells.
    Ogara MF; Rodríguez-Seguí SA; Marini M; Nacht AS; Stortz M; Levi V; Presman DM; Vicent GP; Pecci A
    Nucleic Acids Res; 2019 Nov; 47(20):10645-10661. PubMed ID: 31598691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells.
    Courtin A; Communal L; Vilasco M; Cimino D; Mourra N; de Bortoli M; Taverna D; Faussat AM; Chaouat M; Forgez P; Gompel A
    Breast Cancer Res Treat; 2012 Jan; 131(1):49-63. PubMed ID: 21336598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stress sensing within the breast tumor microenvironment: how glucocorticoid receptors live in the moment.
    Kerkvliet CP; Truong TH; Ostrander JH; Lange CA
    Essays Biochem; 2021 Dec; 65(6):971-983. PubMed ID: 34132331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.